Barclays Downgrades ResMed (RMD) to Underweight
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $221.08 +0.32%
Rating Summary:
11 Buy, 12 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Rating Summary:
11 Buy, 12 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Join SI Premium – FREE
Barclays downgraded ResMed (NYSE: RMD) from Equalweight to Underweight with a price target of $52.00 (from $61.00).
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $53.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- Clean Energy Fuels (CLNE) PT Lowered to $2.50 at Raymond James
- Pony AI Inc (PONY) PT Lowered to $17 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
